AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02372409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02372409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02372409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced (DCE) MRI
Study NCT02372409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic susceptibility contrast (DSC) MRI
Study NCT00679003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLCBT
Description: Social learning and cognitive behavioral therapy
Study NCT00679003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ES
Description: Education and support (information about nutrition and gastrointestinal system)
Study NCT03188939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single injection supraclavicular brachial pleuxus block
Description: the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.
Study NCT03188939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracluster injection supraclavicular brachial pieuxus block
Description: the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
Study NCT03188939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double injection supraclavicular brachial pleuxus block
Description: the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
Study NCT00839072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl
Description: 100 mg immediate-release tablet, dosing q8h
Study NCT00839072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl
Description: 300 mg extended-release caplet, single dose
Study NCT04050293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-538
Description: Patients will receive SPN-538
Study NCT04050293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive Placebo
Study NCT04251000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Joovv Mini
Description: the smallest photomodulation device in the Joovv infrared light product line.
Study NCT03989804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted follow-up
Description: 2 phone calls and 1 e-mail delivered over 6-8 weeks after enrollment aiming to help and support members to get started using the fitness center and its services.
Study NCT02357628 — intervention group
Intervention type: DEVICE
Intervention: Wound treatment with RO-NPT
Study NCT02357628 — intervention group
Intervention type: DEVICE
Intervention: Wound Irrigation
Study NCT03183427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR of the brain
Description: MR of the brain without gadolinium, incl. T2-weighted image
Study NCT01415830 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-scorpion venom serum Birmex
Description: the dose may be required for the patient according to clinical manifestations and evolution
Study NCT01415830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-scorpion venom serum Alacramyn
Description: The dose may be required fot the patient according to clinical manifestations and evolution
Study NCT02379416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib + Paclitaxel
Description: The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
Study NCT04446832 — intervention group
Intervention type: OTHER
Intervention: Vaccine immunogenicity
Description: Evaluation of the vaccine immunogenicity by standard approved serological tests
Study NCT02624518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM2
Description: Imaging with PET/MRI
Study NCT02624518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Imaging with 68Ga-RM2 PET/MRI
Study NCT02624518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Imaging with 68Ga-RM2 PET/MRI
Study NCT01084603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotine
Description: A new l mg oral nicotine product
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 175 mg
Description: ZSP1601 tablets administerekd orally once daily under fasted condition
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 175 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 275 mg
Description: ZSP1601 tablets administered orally once daily in the fasting state
Study NCT01303289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T-Diet plus Standard
Description: T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
Study NCT01303289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jevity
Description: JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 275 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 350 mg
Description: ZSP1601 tablets administered orally once daily under fasted condition
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 350mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 100 mg
Description: ZSP1601 tablets administered orally once daily under fasted or fed condition
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 50 mg
Description: ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 50 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Study NCT01084603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NiQuitinTM Nicotine Lozenge
Description: A marketed 4 mg Nicotine lozenge
Study NCT01084603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette® Nicotine Gum
Description: A marketed 4 mg Nicotine Gum
Study NCT03202628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study NCT03202628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03202628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT03202628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03202628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT02839356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: 20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
Study NCT02839356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 20-mL irrigation with physiological saline over the entire papilla
Study NCT01696383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)
Description: One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
Study NCT03453502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality improvement of breast milk feeding
Description: During the Intervention phase and Sustainability phase ,The NICUs will receive training of multiple evidence based quality improvement methods.
Study NCT00597584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
Study NCT00597584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa or Epoetin beta
Description: Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
Study NCT02568995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine + ketorolac + adrenaline
Description: A combination of drugs injected locally for postoperative pain management
Study NCT02568995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine + ketorolac + adrenaline
Description: A combination of drugs injected locally for postoperative pain management
Study NCT01392859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine 0.5 Mg/mL Oral Solution
Description: Subjects in two arms, will be enrolled in a classical, randomized, double blind, crossover, placebo controlled trial of Levocetirizine(LCT) with determination of the PD response to LCT as determined by suppression of histamine microvasculature response via HILD.
Study NCT03736395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Idaho Rural Implementation Model
Description: The Idaho Rural Implementation Model (I-RIM) includes several aspects to support implementation of schoolwide positive behavioral interventions and supports (SWPBIS). In the first year, schools will send a staff member to a coaching institute to build internal capacity. Schools will also receive technical assistance (on-site twice per year and virtual support as needed). Schools will also receive statewide professional learning opportunities, through one group meeting per year, and through access to an invitation-only professional learning community.
Study NCT03736395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Schools in this condition will receive a four-day training session about SWPBIS.
Study NCT02823873 — intervention group
Intervention type: DEVICE
Intervention: Pulsewave oscillometric wrist cuff blood pressure monitor
Description: Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.
Study NCT05682794 — intervention group
Intervention type: PROCEDURE
Intervention: transanal total mesorectal excision
Description: transanal TME
Study NCT01996176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention consists of four components, which as described below:~1. Information about sedentary behaviour and health: Delivered at the kick-off workshop, in a leaflet and the project website.~2. Local adaptation: Participants adapt the intervention to their personal and local environment setting individual and common goals. Local ambassadors are chosen and support from the management is emphasised.~3. Structural changes: Facilities for standing meetings, both formal and informal. Routes for walking meetings should be defined.~4. Individual support: At the kick-off workshop participants set individual goals. The individual can choose to receive e-mails and text messages (SMS)from the project. The individual receives a post-it block and a postcard to remind them of the project.
Study NCT01996176 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The control group receives the intervention after the last follow-up, the exact time will be settled together with each workplace in the control group.
Study NCT01730859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise and ankle taping
Description: Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.~Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week.
Study NCT04525157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Study NCT04525157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02799316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HBV core antibodies testing. • Real time PCR testing.
Description: * HBV core antibodies testing in HBV surface antigen negative patients.~* Real time PCR testing for those having positive HBc antibodies.
Study NCT00591422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101-C (Darinaparsin)
Description: Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (>36 hours between doses) for 3 weeks with 1 week rest.
Study NCT01735058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.
Study NCT01735058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
Study NCT00409578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
Study NCT00409578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Description: Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
Study NCT00409578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Description: Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
Study NCT00409578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan 300/320 mg
Description: Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
Study NCT03469271 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 1,25 (OH)2 D3
Description: 0.25 micrograms, taken daily for eight weeks, orally
Study NCT03469271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inspiratory isometric resistance training
Description: A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).
Study NCT03469271 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral Placebo
Description: Placebo will be created to mimic the appearance of the study drug
Study NCT03469271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham Inspiratory Isometric Resistance Training
Description: A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.
Study NCT03469271 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Threshold Inspiratory Muscle Trainer (IMT)
Description: A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.
Study NCT01993433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRM02
Study NCT01993433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 100 mg
Description: ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Study NCT03392779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Study NCT04291716 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Motor Seizure Detection Algorithm (mSDA)
Description: A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.
Study NCT01394263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histrelin hydrogel implant
Description: 50 mg histrelin acetate in hyrogel implant